News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
1,375 Results
Type
Article (131)
Press Release (1244)
Section
Business (595)
Career Advice (1)
Deals (88)
Drug Development (297)
FDA (34)
Job Trends (60)
News (985)
Policy (60)
Tag
Academia (3)
Alliances (212)
Alzheimer's disease (1)
Approvals (33)
Best Places to Work (53)
Brain cancer (2)
Cancer (5)
Career advice (1)
CAR-T (1)
Cell therapy (2)
Clinical research (250)
Collaboration (1)
COVID-19 (1)
C-suite (1)
Data (2)
Diagnostics (3)
Earnings (239)
Events (184)
FDA (35)
GLP-1 (13)
Government (3)
Healthcare (12)
Infectious disease (1)
IPO (48)
Job creations (10)
Job search strategy (1)
Legal (16)
Lymphoma (1)
Medical device (3)
Medtech (3)
Mergers & acquisitions (40)
Neuroscience (1)
NextGen Class of 2024 (10)
Non-profit (4)
Northern California (5)
People (127)
Phase I (85)
Phase II (96)
Phase III (94)
Pipeline (2)
Postmarket research (4)
Preclinical (30)
Radiopharmaceuticals (2)
Rare diseases (1)
Real estate (10)
Regulatory (42)
Research institute (2)
Southern California (1)
Startups (11)
Supply chain (2)
United States (21)
Date
Today (1)
Last 7 days (1)
Last 30 days (8)
Last 365 days (63)
2024 (59)
2023 (85)
2022 (108)
2021 (143)
2020 (165)
2019 (90)
2018 (99)
2017 (106)
2016 (53)
2015 (85)
2014 (70)
2013 (53)
2012 (52)
2011 (81)
2010 (56)
Location
Asia (34)
Australia (6)
California (6)
Canada (2)
Europe (615)
Kentucky (1)
Maryland (1)
Massachusetts (9)
New York (2)
North Carolina (2)
Northern California (5)
South America (1)
Southern California (1)
1,375 Results for "servier".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Approvals
Servier Gets FDA Approval for First Targeted Therapy for Grade 2 IDH-Mutant Glioma
Servier Pharmaceuticals’ vorasidenib on Tuesday secured the FDA’s green light for the treatment of patients with grade 2 gliomas carrying mutations in the IDH gene.
August 7, 2024
·
2 min read
·
Tristan Manalac
Genetown
Servier Initiates Critical Dialogue on AYA Cancer Survivorship at ASCO 2024
Servier, a leader in oncology committed to delivering transformative therapies to patients, announced that it will underwrite a panel hosted by The Atlantic.
May 30, 2024
·
3 min read
Genetown
Servier Highlights Commitment to Improving Cancer Outcomes at ASCO 2024
Servier will showcase data from across its oncology portfolio at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31-June 4.
May 23, 2024
·
3 min read
Press Releases
Servier to Present Data on IDH-mutant Glioma at the 2024 Society for Neuro-Oncology (SNO) Congress
November 13, 2024
·
3 min read
Press Releases
Aitia Expand Collaboration with Servier to Discover and Develop New Drugs for Brain Cancer Using AI-Driven Digital Twins
October 30, 2024
·
4 min read
Genetown
Servier Data Presented at AACR Underscores Unwavering Dedication to Advancing Oncology R&D
Servier, a science driven company focused on developing transformative precision therapies for patients, is poised to unveil promising preliminary data at the American Association for Cancer Research Annual Meeting 2024.
April 8, 2024
·
4 min read
Policy
Servier Receives Regulatory Filing Acceptances from FDA and EMA for Vorasidenib in the Treatment of IDH-Mutant Diffuse Glioma
Servier today announced the FDA filing acceptance and priority review for a New Drug Application (NDA) for vorasidenib, as well as the EMA granting accelerated assessment for the vorasidenib Marketing Authorization Application (MAA).
February 21, 2024
·
12 min read
Business
Servier and Base4 Expand Partnership to Advance Neuroscience Drug Development
Base4 Biotechnology (formerly known as Nymirum) today announced that it has expanded its license agreement with Servier to strengthen the companies’ strategic collaboration to develop RNA-targeted small molecule therapeutics.
January 5, 2024
·
2 min read
Drug Development
BioMed X Start Collaboration in Autoimmunity Research with Servier
The new research team at the BioMed X Institute in Heidelberg will develop a novel strategy to selectively target autoreactive plasma cells in autoimmune disease.
June 26, 2024
·
3 min read
FDA
Servier’s VORANIGO® (vorasidenib) Tablets Receives FDA Approval as First Targeted Therapy for Grade 2 IDH-mutant Glioma
August 6, 2024
·
12 min read
1 of 138
Next
